Winning the Battle of High Failure Rates in Drug Discovery

738 views

Published on

Winning the Battle of High Failure Rates in Drug Discovery: Interview with: Professor Theo Meert, Senior Director External Innovations NS, Janssen Research & Development, Johnson & Johnson, a speaker at the marcus evans Discovery Summit 2012, shares strategies for improving drug discovery efforts.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
738
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Winning the Battle of High Failure Rates in Drug Discovery

  1. 1. Winning the Battle of High Failure Rates in Drug Discovery continue to invest. Together with the from human tissue based approaches, complexities involved in understanding diseased and not, such as genetics, the chronic brain disorders, discovery various forms of omics, IPS cells, and efforts are demanding and need a so on, which in the past were easier to multidisciplinary approach, often access in oncology than in the involving various partners. neurosciences. Also advances in the area of imaging, electronic recordings How can pharma companies win the and (in vivo) electrophysiology are battle of high failure rates? giving us a more in-depth understanding of neuronal connectivity Several processes are proving to be and thus global functioning of the brain. successful when it comes to target All these technological evolutions, validation and POC. Scientists should together with a better recording and useInterview with: Professor Theo ensure that targets are expressed/ of patient databases (medical healthMeert, Senior Director External engaged in the human pathological care records) help to drive the scienceInnovations NS, Janssen Research conditions and strive to have a better forward.& Development, Johnson & Johnson understanding of the disease (progression) itself through systems Why do you consider open biology. This would be a good starting collaboration in this field essential?The failure rate across the different point.stages of drug development have Although there is a natural competitionbeen increasing over the years, but A good interaction with principal between pharmaceutical companies forthere could be ways around it, says investigators within different expertises the compound/treatment itself, a lot ofProfessor Theo Meert, Senior Director in areas of focused research and moving the science could be done in a pre-External Innovations NS, Janssen away from the classical ways of competitive space, through partnershipsResearch & Development, Johnson & developing and testing drugs is what is between companies and academia.Johnson. A speaker at the marcus often needed. Scientists can utilise Publishing negative results of clinicalevans Discovery Summit 2012, different kind of biomarkers, various trials and using community funding inwhich took place in Cannes, France, technologies to integrate different kind collaboration would also move science22 - 23 March, Meert talked about drug of biological data which can be ahead. A more holistic approach both indiscovery in Neuroscience (NS) and collected, stratify patient populations, drug development but also in treatmentshared target validation and Proof of use translational experimental medicine strategies will give us a better successConcept (POC) testing strategies. approaches and use integrated in our challenge to treat some of databases of patient recordings. humanities’ most devastating illnesses.Why have some pharmaceuticalcompanies trimmed down their At present, drug development costsdiscovery efforts? around USD 2 billion and in some casesOne issue is the challenges of bringing it can take up to 15 years. A more stratified experimental approach, using A moreforth novel Central Nervous System(CNS) medicines. The work required integrated approaches and targeting the relevant targets in sub-populations of holistic approachto get a compound approved hasincreased, especially since the patients could reduce the overall cost of development. The formation of would give us aenv iron me n t de man ds in crea se defficacy/ differentiation against existing international consortia with pre - competitive research would also help to better success intherapies, and this is what is needed totruly transform care for patients. It has reduce costs of target validation, biomarker development, human POC our challenge tobecome harder to validate novel drugtargets related to disease modification, testing and should contribute to an increased scientific knowledge of treat some ofboth in terms of pre-clinical and POC inthe clinic itself. Generic drugs are also disease chronification in various CNS disorders. humanities’ mosthaving an important impact, with manycompanies losing patents in the CNS In drug discovery, what are some of devastatingarea, reducing the amount of moneythat can be spent in research. At the scientific areas or technologies worth following? illnessesJanssen, however, we continue to befully committed to CNS research and We are seeing more approaches starting
  2. 2. About the Discovery Summit 2012 The Pharma Network - marcus evans Summits group This unique forum took place at the Majestic Barrière Hotel, Cannes, France, 22 - 23 delivers peer-to-peer information March 2012. Offering much more than any conference, exhibition or trade show, on strategic matters, professional this exclusive meeting brought together esteemed industry thought leaders and trends and breakthrough solution providers to a highly focused and interactive networking event. The innovations. Summit included presentations on ensuring successful drug discovery, stimulating innovation and creating partnerships. www.discovery-summit.com Please note that the Summit is a Contact closed business event and the Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division number of participants strictly limited. Tel: + 357 22 849 313 Email: press@marcusevanscy.com For more information please send an email to info@marcusevanscy.com All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.comAbout marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discussstrategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity toindividually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.For more information, please visit: www.marcusevans.comUpcoming EventsDiscovery Summit (North America) - www.thediscoverysummit.comEvolution Asia Summit (Asia Pacific) - www.evolutionasia-summit.comEvolution Summit (Europe) - www.evolution-summit.comEvolution Summit (North America) - www.evolutionsummit.comTo view the web version of this interview please click here: www.discovery-summit.com/TheoMeert

×